Purchase this article with an account.
Terry Bowlin, Islam Hussein, Eric G Romanowski; Evaluation of Filociclovir as a Potent Antiviral for Ocular Adenoviral Infections. Invest. Ophthalmol. Vis. Sci. 2020;61(7):422.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
There is currently no approved antiviral treatment for adenoviral conjunctivitis, which is often associated with significant morbidity. These studies tested the antiviral activity of the novel broad-spectrum nucleoside analog, filociclovir (FCV), by determining the in vitro IC50 concentrations (concentrations that inhibit adenovirus plaque formation by 50%) of FCV and cidofovir (CDV), against a panel of seven (7) ocular adenovirus serotypes.
In vitro, the 50% inhibitory concentrations (IC50) of FCV and CDV were determined using standard plaque-reduction assays on A549 lung adenocarcinoma cells. Briefly, Ad3, Ad4, Ad5, Ad7a, Ad8, Ad19/64 and Ad37 were adsorbed on the A549 cells then treated with final concentrations of FCV and CDV of 100, 10, 1.0, 0.1, 0.01 and 0.001 µM and the antiviral activity of FCV and CDV were then quantified by plaque assay, done in triplicate.
The mean in vitro IC50 for FCV ranged from 0.496 to 4.684 µM, whereas those for CDV ranged from 0.487 to 30.304 µM. FCV was more potent than CDV for five of the seven serotypes. See Table.
FCV demonstrated potent anti-adenovirus activity in vitro. Tolerability and efficacy studies after topical ocular administration in the rabbit eye model are currently underway to evaluate FCV as a topical antiviral treatment for ocular adenoviral infections.
This is a 2020 ARVO Annual Meeting abstract.
In vitro activity of filociclovir and cidofovir against a panel of 7 ocular adenovirus serotypes
This PDF is available to Subscribers Only